Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN) -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (246)	4/15/1999 9:07:00 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 1475

XOMA/GNE phase II results are out for phase II. Looks like hu1124 is definitely active. Also looks like there's room for improvement...... Preliminary analysis of data from this study, completed late in 1998, showed excellent clinical improvement, as measured by Physician's Global Assessment, in 25% of the patients treated with hu1124 versus 2% of the patients in the placebo group. These results were statistically significant (p(less than) .005). Additionally, 47% of the patients in the hu1124 group showed good or better improvement versus 15% of the patients in the placebo group. These results were also statistically significant (p(less than) .005). Overall, the drug appeared to be well tolerated. The most common adverse events were mild headaches and low grade temperature elevations, most notably after the first dose.